176 related articles for article (PubMed ID: 1694429)
21. Delineation of a neutralizing subregion within the immunodominant epitope (GH loop) of foot-and-mouth disease virus VP1 which does not contain the RGD motif.
Brown F; Benkirane N; Limal D; Halimi H; Newman JF; Van Regenmortel MH; Briand JP; Muller S
Vaccine; 1999 Aug; 18(1-2):50-6. PubMed ID: 10501234
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of synthetic peptide candidate vaccines against serotype-A foot-and-mouth disease virus in cattle.
Zhang Z; Pan L; Ding Y; Zhou P; Lv J; Chen H; Fang Y; Liu X; Chang H; Zhang J; Shao J; Lin T; Zhao F; Zhang Y; Wang Y
Appl Microbiol Biotechnol; 2015 Feb; 99(3):1389-98. PubMed ID: 25381487
[TBL] [Abstract][Full Text] [Related]
23. Identification of a major antibody binding epitope in the non-structural protein 3D of foot-and-mouth disease virus in cattle and the development of a monoclonal antibody with diagnostic applications.
Yang M; Clavijo A; Li M; Hole K; Holland H; Wang H; Deng MY
J Immunol Methods; 2007 Apr; 321(1-2):174-81. PubMed ID: 17320098
[TBL] [Abstract][Full Text] [Related]
24. Analysis of foot-and-mouth disease virus type O1 Brugge neutralization epitopes using monoclonal antibodies.
Stave JW; Card JL; Morgan DO
J Gen Virol; 1986 Oct; 67 ( Pt 10)():2083-92. PubMed ID: 2428926
[TBL] [Abstract][Full Text] [Related]
25. Recognition of foot-and-mouth disease virus and its capsid protein VP1 by bovine peripheral T lymphocytes.
Garcia-Valcarcel M; Doel T; Collen T; Ryan M; Parkhouse RM
J Gen Virol; 1996 Apr; 77 ( Pt 4)():727-35. PubMed ID: 8627261
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of a recombinant fusion protein of tandem repeat epitopes of foot-and-mouth disease virus type Asia 1 for guinea pigs.
Zhang Q; Yang YQ; Zhang ZY; Li L; Yan WY; Jiang WJ; Xin AG; Lei CX; Zheng ZX
Acta Virol; 2002; 46(1):1-9. PubMed ID: 12199204
[TBL] [Abstract][Full Text] [Related]
27. The potential of retro-inverso peptides as synthetic vaccines.
Van Regenmortel MH; Guichard G; Benkirane N; Briand JP; Muller S; Brown F
Dev Biol Stand; 1998; 92():139-43. PubMed ID: 9554267
[TBL] [Abstract][Full Text] [Related]
28. Serological prospects for peptide vaccines against foot-and-mouth disease virus.
Parry NR; Ouldridge EJ; Barnett PV; Clarke BE; Francis MJ; Fox JD; Rowlands DJ; Brown F
J Gen Virol; 1989 Nov; 70 ( Pt 11)():2919-30. PubMed ID: 2479714
[TBL] [Abstract][Full Text] [Related]
29. Strategy for producing new foot-and-mouth disease vaccines that display complex epitopes.
McKenna TS; Rieder E; Lubroth J; Burrage T; Baxt B; Mason PW
J Biotechnol; 1996 Jan; 44(1-3):83-9. PubMed ID: 8717390
[TBL] [Abstract][Full Text] [Related]
30. Structures of Foot-and-Mouth Disease Virus with Bovine Neutralizing Antibodies Reveal the Determinant of Intraserotype Cross-Neutralization.
He Y; Li K; Wang L; Sun Z; Cao Y; Li P; Sun P; Bao H; Zhou S; Wang S; Bai X; Liu X; Zhao L; Fan X; Liu Z; Lu Z; Yang C; Lou Z
J Virol; 2021 Nov; 95(24):e0130821. PubMed ID: 34586859
[TBL] [Abstract][Full Text] [Related]
31. Mimicry of viral epitopes with retro-inverso peptides of increased stability.
Benkirane N; Guichard G; Briand JP; Muller S; Brown F; Van Regenmortel MH
Dev Biol Stand; 1996; 87():283-91. PubMed ID: 8854029
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the antibodies elicited by the individual structural polypeptides of foot-and mouth disease and polio viruses.
Meloen RH; Rowlands DJ; Brown F
J Gen Virol; 1979 Dec; 45(3):761-3. PubMed ID: 94352
[TBL] [Abstract][Full Text] [Related]
33. Immunization against foot-and-mouth disease with synthetic peptides representing the C-terminal region of VP1.
Doel TR; Gale C; Brooke G; DiMarchi R
J Gen Virol; 1988 Sep; 69 ( Pt 9)():2403-6. PubMed ID: 2457649
[TBL] [Abstract][Full Text] [Related]
34. Bovine herpesvirus-1 (infectious bovine rhinotracheitis virus)-based viral vector which expresses foot-and-mouth disease epitopes.
Kit M; Kit S; Little SP; Di Marchi RD; Gale C
Vaccine; 1991 Aug; 9(8):564-72. PubMed ID: 1722936
[TBL] [Abstract][Full Text] [Related]
35. Neutralizing epitopes of type O foot-and-mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents.
Parry NR; Barnett PV; Ouldridge EJ; Rowlands DJ; Brown F
J Gen Virol; 1989 Jun; 70 ( Pt 6)():1493-503. PubMed ID: 2471812
[TBL] [Abstract][Full Text] [Related]
36. Correlation between efficacy and structure of recombinant epitope vaccines against bovine type O foot and mouth disease virus.
Fang M; Li J; Wang H; Yang M; Zhang Y; Zhou L; Wei H; Yang G; Yu Y; Wei X; Yu Y; Wang L; Wan M
Biotechnol Lett; 2012 May; 34(5):839-47. PubMed ID: 22286179
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of an aphthovirus chimera of the glycoprotein of vesicular stomatitis virus.
Grigera PR; Garcia-Briones M; Periolo O; la Torre JL; Wagner RR
J Virol; 1996 Dec; 70(12):8492-501. PubMed ID: 8970972
[TBL] [Abstract][Full Text] [Related]
38. Proliferative lymphocyte responses to foot-and-mouth disease virus and three FMDV peptides after vaccination or immunization with these peptides in cattle.
van Lierop MJ; van Maanen K; Meloen RH; Rutten VP; de Jong MA; Hensen EJ
Immunology; 1992 Mar; 75(3):406-13. PubMed ID: 1349300
[TBL] [Abstract][Full Text] [Related]
39. [Synthetic immunogenic complexes containing a peptide from the surface protein of the foot-and-mouth disease virus].
Rar VA; Makarov EA; Iurovskiĭ VV; Meshcheriakova EA; Andronova TM; Ivanov VT
Bioorg Khim; 1990 Jul; 16(7):904-15. PubMed ID: 2173604
[TBL] [Abstract][Full Text] [Related]
40. Characterization and immune response of a protein produced by a cDNA clone of foot and mouth disease virus, type Asia 1 63/72.
Suryanarayana VV; Venkataramanan R; Rao BU; Padayatty JD
Biochem Int; 1992 May; 26(6):1003-16. PubMed ID: 1378734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
